June 2008
PharmaWatch: Biotechnology;Jun2008, Vol. 7 Issue 6, p22
Market Research Report
The article presents a corporate profile of biopharmaceutical firm UCB Pharma. UCB is a global firm involved in the research, development and marketing of pharmaceutical and biotechnology products in the areas of central nervous system (CNS) disorders and allergy/respiratory diseases. Its primary care products include Metadate-CDT for the treatment of attention deficit-hyperactivity disorder (ADHD) and Nootropil for the treatment of vertigo and events related to ageing.


Related Articles

  • Infliximab: An Updated Review of its Use in Crohn's Disease and Rheumatoid Arthritis. Keating, G.M.; Perry, C.M. // BioDrugs;2002, Vol. 16 Issue 2, p111 

    Infliximab is a chimeric monoclonal antibody that binds to tumour necrosis factor-α (TNFα) and neutralises its effects. TNFα plays an important role in the development of both Crohn's disease and rheumatoid arthritis. In a large, double-blind, randomised study involving patients with...

  • UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.  // Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p2 

    The article reports that UCB got positive results for signs and symptoms from two Cimzia phase III studies in the treatment of rheumatoid arthritis. UCB has also received a complete response letter from the U.S. Food and Drug Administration requesting additional information and clarification on...

  • New Hope for Survivors of Stroke and Traumatic Brain Injury. Clark, Ian // CNS Drugs;2012, Vol. 26 Issue 12, p1071 

    The author reflects on the improvements in the clinical parameters associated with the stroke and traumatic brain injury. He offers information on the etanercept which is a specific anti-tumour necrosis factor (TNF) biological agents used for treating several autoimmune diseases including...

  • Adalimumab. Edwards, Lisa A. // Formulary;May2003, Vol. 38 Issue 5, p272 

    Discusses the efficacy of Adalimumab, a tumor necrosis factor-alpha inhibitor in the treatment of rheumatoid arthritis. Role in the slow progression of joint damage and improvement in the quality of life of patients; Effectiveness when used alone or in combination with methotrexate or...

  • New treatment for rheumatoid arthritis? Too soon to tell.  // Mayo Clinic Health Letter;Jan1995, Vol. 13 Issue 1, p3 

    Reports on a new treatment that can reduce joint pain, swelling and stiffness in people with rheumatoid arthritis according to the October 22, 1994 issue of the `Lancet.' Attack on a protein called tumor necrosis factor (TNF); Study's provision of insight into the inflammatory process of...

  • Targeting Tumour Necrosis Factor in the Treatment of Rheumatoid Arthritis. Pearce, G.J.; Chikanza, I.C. // BioDrugs;2001, Vol. 15 Issue 3, p139 

    Inflammation in rheumatoid arthritis (RA) is associated with an imbalance between pro- and anti-inflammatory factors, which leads to a persistent chronic inflammatory state in the joint. Molecular studies of the physiology of the inflammatory response have identified a hierarchy of cytokine...

  • Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis: Focus on the Soluble TNF Receptor p75 Fusion Protein, Etanercept. Moreland, L.W. // BioDrugs;1999, Vol. 11 Issue 3, p201 

    Tumour necrosis factor (TNF) is the dominant mediator of the cytokine cascade that causes inflammation and joint detruction in rheumatoid arthritis. A new class of agents under investigation, the biological TNF inhibitors, inhibit the activity of TNF. Recombinant human TNF receptor p75 Fc fusion...

  • Criteria for TNF-Targeted Therapy in Rheumatoid Arthritis: Estimates of the Number of Patients Potentially Eligible. Kvien, T.K.; Uhlig, T.; Kristiansen, I.S. // Drugs;Sep2001, Vol. 61 Issue 12, p1711 

    Tumour necrosis factor (TNF) antagonists or blocking agents represent a major advance in the treatment of rheumatoid arthritis (RA), but their use raises economic concerns because of the high drug cost. Population-based patient registers with clinical data allow the estimation of the proportion...

  • Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (Remission Induction by Remicade in RA) study.  // International Journal of Advances in Rheumatology;2010, Vol. 8 Issue 4, p149 

    The article presents a research that investigates the effectiveness of the combination of infliximab and tumor necrosis factor (TNF) in treating rheumatoid arthritis (RA).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics